Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfaf193 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Lin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Biomarkers. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Acute graft-versus-host disease (aGVHD) is a common complication of allogenic hematopoietic cell transplantation (HCT). The aGVHD presymptomatic algorithm is comprised of 2 serum biomarkers, suppression of tumorigenicity 2 and regenerating islet-derived 3-alpha. This test was developed to predict severe aGVHD and 6-month nonrelapse mortality (NRM) in allogeneic HCT recipients.
Methods
The medical records of 223 patients tested with the aGVHD presymptomatic algorithm between January 2020 and June 2024 were retrospectively reviewed. Sensitivity and specificity for the prediction of severe aGVHD (grade III or IV) and 6-month NRM were determined. Logistic regression modeling was used to assess the odds ratios of risk factors for severe aGVHD and 6-month NRM. The likelihood ratio test was used to evaluate whether the addition of the aGVHD presymptomatic algorithm improved model fit.
Results
Severe aGVHD occurred in 8.5% of patients, and 6-month NRM was 7.2%. The aGVHD presymptomatic algorithm demonstrated a sensitivity of 21.1% (95% CI, 8.0%–43.9%) and specificity of 83.3% (95% CI, 77.6%–87.9%) for severe aGVHD and a sensitivity of 43.8% (95% CI, 23.1%–66.8%) and specificity of 85.0% (95% CI, 79.5%–89.3%) for 6-month NRM. The addition of results from the aGVHD presymptomatic algorithm to conventional risk factors did not improve prediction of aGVHD but improved prediction of 6-month NRM.
Conclusions
The aGVHD presymptomatic algorithm was suboptimal for routine clinical use. Further development of predictive aGVHD biomarkers may be required to aid in the management of allogeneic HCT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Division of Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, United States.
- Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, United States.
Zitieren
APA
Wang, L., Pulgrossi, R. C., Anderson, J., Garcia, A., Meyer, E. H., Zehnder, J. L., & Pinsky, B. A. (2026). Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf193
Vancouver
Wang L, Pulgrossi RC, Anderson J, Garcia A, Meyer EH, Zehnder JL, et al. Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf193
BibTeX
@article{Wang2026,
author = {Wang, Lin and Pulgrossi, Rafael C and Anderson, Jaclyn and Garcia, Ariadna and Meyer, Everett H and Zehnder, James L and Pinsky, Benjamin A},
title = {Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfaf193}
}
EUVIMED